Keyphrases
Ribavirin
70%
Co-infected Patients
57%
Pegylated Interferon
43%
Hepatitis C Virus
32%
Tolerability
27%
SVR12
27%
Genotype 1
22%
Ribavirin-induced Anemia
21%
ITPA Gene
21%
Faldaprevir
21%
Giant Cell (temporal) Arteritis
21%
Effective Model
21%
Emergency Service
21%
Direct-acting Antivirals
21%
Churg-Strauss Syndrome
21%
Hepatic Decompensation
21%
Nevirapine
21%
Antineutrophil Cytoplasmic Antibody
21%
Neuropsychiatric Symptoms
21%
Sofosbuvir
21%
Combination Therapy
21%
Hepatitis C Virus Genotypes
21%
Gene Polymorphism
21%
Antiviral Drugs
21%
HIV-HCV
21%
Care Planning
21%
Liver Stiffness
21%
Telaprevir
21%
Predictive Factors
21%
Janus Kinase Inhibitors
21%
Rheumatoid Arthritis
21%
Inhibitor Study
21%
Adverse Reactions
21%
Genotype
19%
Odds Ratio
18%
Confidence Interval
18%
Drug Side Effects
14%
Patient Transfer
14%
Triple Therapy
14%
High Complexity
14%
Risk Factors
12%
Treatment Failure
12%
HCV RNA
12%
Inhibitor Treatment
12%
Sustained Virological Response
11%
Efavirenz
10%
Ledipasvir
10%
Pretreated Patients
10%
Dose Reduction
10%
Liver Cirrhosis
9%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Ribavirin
81%
Peginterferon
46%
Hepatitis C Virus
36%
Tolerability
27%
Faldaprevir
21%
Anemia
21%
Decompensated Liver Cirrhosis
21%
Telaprevir
21%
Intervention Study
21%
Hepatitis C Virus Genotype 1
21%
Combination Therapy
21%
Hospital Pharmacy
21%
Antivirus Agent
21%
Nevirapine
21%
Janus Kinase Inhibitor
21%
Rheumatoid Arthritis
21%
Adverse Event
21%
Inflammatory Arthritis
21%
Side Effect
18%
Liver Cirrhosis
11%
Efavirenz
10%
Sofosbuvir
10%
Ledipasvir Plus Sofosbuvir
10%
Infection
9%
Gastrointestinal Disease
9%
Observational Study
7%
Rash
7%
Hepatitis C
7%
Erythropoietin
6%
Adverse Drug Reaction
6%
Brain Disease
5%
Simeprevir
5%
Viral Clearance
5%
Daclatasvir
5%
Clinical Trial
5%
Ascites
5%